MoonLake Immunotherapeutics (MLTX) stock: key figures, P/E, revenue and dividend
Health Care · Switzerland · ISIN US61559X1046
MoonLake Immunotherapeutics financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -244.83 m USD |
| EBIT | -222.46 m USD |
| Net income | -227.32 m USD |
| Diluted EPS – continuing operations | -3.53 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
More stocks
- Beijing Zhidemai Technology (300785.SZ)
- Dazzle Fashion Co Ltd (603587.SS)
- Rastar Environmental Protection Materials Co.Ltd. (300834.SZ)
- Sats ASA (SATS.OL)
- Polar Capital Holdings PLC (POLR.L)
- Sabine Royalty Trust (SBR)
- HTC Corp (2498.TW)
- Kolon Industries Inc (120110.KS)
- Tamboran Resources Corp (TBN)
- Eckert & Ziegler (EUZ.DE)
- DroneShield Ltd (DRO.AX)
- Jiangsu Zhongchao Cable Co Ltd (002471.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.